# 1 A machine-learning model to harmonize brain volumetric data for quantitative neuro-radiological

- 2 assessment of Alzheimer's disease
- 3 Authors:
- 4 Damiano Archetti<sup>1,\*</sup>, Vikram Venkatraghavan<sup>2,3,\*</sup>, Béla Weiss<sup>4,5</sup>, Pierrick Bourgeat<sup>6</sup>, Tibor Auer<sup>4,7</sup>,
- 5 Zoltán Vidnyánszky<sup>4</sup>, Stanley Durrleman<sup>8</sup>, Wiesje M. van der Flier<sup>2,3,9</sup>, Frederik Barkhof<sup>10,11,12</sup>, Daniel
- 6 C. Alexander<sup>12</sup>, Andre Altmann<sup>12</sup>, Alberto Redolfi<sup>1</sup>, Betty M. Tijms<sup>2,3</sup>, Neil P. Oxtoby<sup>12</sup>, for the
- 7 Australian Imaging Biomarkers and Lifestyle Study<sup>†</sup>, for the Alzheimer's Disease Neuroimaging
- 8 Initiative<sup>‡</sup>, and for the E-DADS Consortium
- 9 1 Laboratory of Neuroinformatics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia,
- 10 Italy;
- 11 2 Alzheimer Center Amsterdam, Neurology, Vrije Universiteit, Amsterdam UMC, location VUmc,
- 12 Amsterdam, the Netherlands;
- 13 3. Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands;
- 14 4 Brain Imaging Centre, Research Centre for Natural Sciences, Budapest, Hungary;
- 15 5 Biomatics and Applied Artificial Intelligence Institute, John von Neumann Faculty of
- 16 Informatics, Óbuda University, Budapest, Hungary
- 17 6 The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, Queensland,
- 18 Australia;
- 19 7 School of Psychology, University of Surrey, Guildford, United Kingdom;
- 20 8 Sorbonne Université, Institut du Cerveau Paris Brain Institute ICM, CNRS, Inria, Inserm, AP-HP,
- 21 Hôpital Pitié-Salpêtrière, Paris, France;
- 22 9 Department of Epidemiology and Data Science, Vrije Universiteit, Amsterdam UMC, location
- 23 VUmc, the Netherlands;
- 24 10 Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, the
- 25 Netherlands;
- 26 11 Queen Square Institute of Neurology, University College London, United Kingdom;
- 27 12 UCL Centre for Medical Image Computing, Department of Medical Physics and Biomedical
- 28 Engineering and Department of Computer Science, University College London, United Kingdom; NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 29 \*Indicates shared first co-authorship, with the first co-authors being listed alphabetically.
- 30 <sup>+</sup> Data used in the preparation of this article was obtained from the Australian Imaging Biomarkers
- 31 and Lifestyle (AIBL) Study. Unless named, the AIBL researchers contributed data but did not
- 32 participate in analysis or writing of this report. AIBL researchers are listed at <u>https://aibl.org.au</u>
- 33 ‡ Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging
- 34 Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed
- 35 to the design and implementation of ADNI and/or provided data but did not participate in analysis or
- 36 writing of this report. A complete listing of ADNI investigators can be found at:
- 37 http://adni.loni.usc.edu/wp-content/uploads/how\_to\_apply/ADNI\_Acknowledgement\_List.pdf.

# 38 Corresponding author:

- 39 Damiano Archetti (OrcID: 0000-0003-0818-7685)
- 40 E-mail: <u>darchetti@fatebenefratelli.eu</u>
- 41 Phone: +39 0303501502
- 42 Address: Via Pilastroni 4, Brescia, 25125, Italy

# 43 Contributors' contacts

- 44 Vikram Venkatraghavan (OrcID: 0000-0001-9759-0462): v.venkatraghavan@amsterdamumc.nl
- 45 Béla Weiss (OrcID: 0000-0003-1031-0283): <u>weiss.bela@ttk.hu</u>
- 46 Pierrick Bourgeat (OrcID: 0000-0002-2605-4766): pierrick.bourgeat@csiro.au
- 47 Tibor Auer (OrcID: 0000-0001-5153-1424): <u>t.auer@surrey.ac.uk</u>
- 48 Zoltán Vidnyánszky (OrcID: 0000-0003-3914-3087): vidnyanszky.zoltan@ttk.hu
- 49 Stanley Durrleman (OrcID: 0000-0002-9450-6920): <u>stanley.durrleman@inria.fr</u>
- 50 Wiesje M. van der Flier (OrcID: 0000-0001-8766-6224): <u>wm.vdflier@amsterdamumc.nl</u>
- 51 Frederik Barkhof (OrcID: 0000-0003-3543-3706): <u>f.barkhof@amsterdamumc.nl</u>
- 52 Daniel C Alexander (OrcID: 0000-0003-2439-350X): <u>d.alexander@ucl.ac.uk</u>
- 53 Andre Altmann (OrcID: 0000-0002-9265-2393): <u>a.altmann@ucl.ac.uk</u>
- 54 Alberto Redolfi (OrcID: 0000-0002-4145-9059): <u>aredolfi@fatebenefratelli.eu</u>
- 55 Betty M. Tijms (OrclD: 0000-0002-2612-1797): <u>b.tijms@amsterdamumc.nl</u>

#### 56 Neil P Oxtoby (OrcID: 0000-0003-0203-3909): <u>n.oxtoby@ucl.ac.uk</u>

# 57 Abstract:

58 **Background**: Structural MRI plays a pivotal role in the radiological workup for assessing 59 neurodegeneration. Scanner-related differences hinder quantitative neuroradiological assessment of 60 Alzheimer's disease (QNAD). This study aims to train a machine-learning model to harmonize brain 61 volumetric data of patients not encountered during model training.

62 Method: Neuroharmony is a recently developed method that uses image quality metrics (IQM) as 63 predictors to remove scanner-related effects in brain-volumetric data using random forest regression. 64 To account for the interactions between AD-pathology and IQM during harmonization, we developed 65 a multi-class extension of Neuroharmony. We performed cross-validation experiments to benchmark performance against existing approaches using data from 20,864 participants comprising cognitively 66 67 unimpaired (CU) and impaired (CI) individuals, spanning 11 cohorts and 43 scanners. Evaluation 68 metrics assessed ability to remove scanner-related variations in brain volumes (biomarker 69 concordance), while retaining the ability to delineate different diagnostic groups (preserving disease-70 related signal).

**Results**: For each strategy, biomarker concordances between scanners were significantly better ( $p < 10^{-6}$ ) compared to pre-harmonized data. The proposed multi-class model achieved significantly higher concordance than the Neuroharmony model trained on CU individuals (CI:  $p < 10^{-6}$ , CU: p = 0.02) and preserved disease-related signal better than the Neuroharmony model trained on all individuals without our proposed extension ( $\Delta AUC = -0.09$ ). The biomarker concordance was better in scanners seen during training (concordance > 97%) than unseen (concordance < 79%), independent of cognitive status.

Conclusion: In a large-scale multi-center dataset, our proposed multi-class Neuroharmony model
 outperformed other strategies available for harmonizing brain-volumetric data in a clinical setting.
 This paves the way for enabling QNAD in the future.

#### 81 1 Introduction

82 Structural MRI such as T1-weighted (T1w) sequences are routinely acquired in memory clinics for diagnosing Alzheimer's disease (AD)<sup>1</sup>, clinical phenotyping<sup>2</sup>, and for differentiating AD from other 83 types of dementias<sup>3</sup>. In current clinical practice, radiologists primarily assess global and regional 84 85 atrophy through visual examination of MRI. However, visual examinations are subjective and prone to intra-rater and inter-rater variability. Quantitative imaging biomarkers such as brain volumetric 86 87 data are becoming increasingly popular because of their potential to improve diagnostic confidence<sup>4</sup>. 88 Quantitative imaging biomarkers can be used for objective assessment in the radiological workflow 89 either by using automated digital tools based on normative modelling<sup>3</sup> or using latest advances in artificial intelligence such as brain-age estimation<sup>5</sup>, or data-driven subtyping<sup>6</sup>. 90

91 However, differences in MRI acquisition protocols and scanners affect consistency and reproducibility 92 of brain volumetry<sup>7</sup> and are a major impediment for the clinical translation to automated tools. To tackle this problem, many harmonization tools have emerged in recent years<sup>8</sup>. Such algorithms can 93 94 either harmonize original scans<sup>9</sup> or derivatives extracted from the scans<sup>10</sup>. Some of these algorithms have been shown to harmonize patient data affected by a neurodegenerative disease<sup>11,12</sup>, while 95 preserving disease-related signature. However, such harmonization techniques typically work only for 96 the scanner models they have been trained on, and, in some instances require the same subjects to 97 be scanned with multiple different scanners<sup>13</sup>. Harmonizing volumetric data from MRI scanners not 98 99 encountered during initial model training needs additional training with a substantial number of images from these scanners<sup>14</sup>. This poses a challenge for the deployment of such methods for clinical 100 101 use.

Neuroharmony<sup>15</sup> is a recently developed harmonization approach that can harmonize volumetric data from new and unseen MRI scanners. It works under the assumption that the corrections needed to harmonize data from multiple scanners can be predicted from image quality metrics (IQM) computed from the scans. While the original experiments indicate that harmonization works for healthy controls, harmonizing data from patients with neurodegenerative diseases remains an open problem. This is because disease pathology in patients may affect the IQM, and such effects remain unaccounted for in a Neuroharmony model trained on healthy controls.

In this paper we propose an extension of Neuroharmony to account for interaction between disease pathology and IQM to remove scanner-related effects (multi-class model of Neuroharmony). We systematically compare the performances of the proposed multi-class model in harmonizing data with two other approaches: the original Neuroharmony model trained only on cognitively unimpaired (CU) individuals (normative model of Neuroharmony) and the original Neuroharmony model trained on

- 114 cognitively unimpaired as well as cognitively impaired (CI) individuals without our proposed multi-
- 115 class extension (inclusive model of Neuroharmony). We used data from 11 cohorts across three
- 116 continents for evaluating these approaches. Lastly, we identify key challenges for clinical
- 117 implementation of the best multicentric harmonization strategy identified in our experiments for
- 118 enabling quantitative neuroradiological assessment of Alzheimer's disease (QNAD).

#### 119 2 Materials and Methods

# 120 <u>2.1 Participants and scanner characteristics</u>

T1w MRI data of healthy controls (CN), participants with subjective cognitive decline (SCD), mild 121 122 cognitive impairment (MCI), and Alzheimer's disease (AD) from 11 data cohorts were included in our analysis. The cohorts considered for this study were: Amsterdam Dementia Cohort (ADC)<sup>16</sup>, 123 124 Alzheimer's Disease Neuroimaging Initiative (ADNI)<sup>17</sup>, Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL)<sup>18</sup>, Alzheimer's Repository Without Borders (ARWiBo)<sup>19</sup>, European DTI 125 Study on Dementia (EDSD)<sup>20</sup>, Hungarian Longitudinal Study of Healthy Brain Aging (HuBA)<sup>21</sup>, Italian 126 127 Alzheimer's Disease Neuroimaging Initiative (I-ADNI)<sup>22</sup>, National Alzheimer's Coordination Center (NACC) <sup>23</sup>, Open Access Series of Imaging Studies (OASIS, versions 1&2)<sup>24</sup>, European Alzheimer's 128 129 Disease Neuroimaging Initiative (also known as PharmaCOG)<sup>25</sup>, and UK Bio-bank (UKBB)<sup>26</sup>. Detailed 130 information about each cohort is summarized in Supplementary Table 1.

Minimum inclusion criteria included the availability of a T1w MRI scan along with age, sex, scanner information, and a clinical diagnosis of either CN, SCD, MCI or AD. All datasets were organized according to the BIDS standard<sup>27</sup> to ensure inter-operability and data anonymization. An overview of the scanners used in this study is shown in Table 1.

#### 135 <u>2.2 Image processing</u>

136 Cortical reconstruction and volumetric segmentation were performed with the cross-sectional pipeline of FreeSurfer v7.1.1<sup>28</sup> in order to extract volumes of 68 cortical regions in the Desikan-Killiany 137 138 atlas, 14 subcortical brain regions, as well as total CSF volume, total gray matter volume and total brain volume with and without ventricles. All features derived from FreeSurfer are listed in 139 140 Supplementary Figure 1. IQM were estimated using MRIQC v0.16.1<sup>29</sup>. Automatic quality control of the 141 FreeSurfer segmentations was performed using the Euler number, where outliers defined as 1.5×IQR (inter-quartile range) below the first quartile and 1.5×IQR above the third quartile<sup>30</sup> per scanner were 142 143 excluded from our experiments.

In order to ensure reproducibility of our results across different computing environments<sup>31</sup>, Docker
 containers for both FreeSurfer (<u>https://github.com/E-DADS/freesurfer</u>) and MRIQC
 (<u>https://github.com/E-DADS/mriqc</u>) have been made available online.

### 147 <u>2.3 Multi-class Neuroharmony model</u>

148 The volumetric data from all individuals in the training set were harmonized using ComBat 149 harmonization<sup>10</sup> with empirical Bayes optimization, for removing scanner related batch effects while

150 preserving the effects of age, sex, and cognitive status. The cognitive status was dichotomized based 151 on the clinical diagnosis as either CU (CN and SCD) or CI (MCI and AD). Subsequently, a random forest 152 regressor was trained with MRIQC-derived IQM to predict the corrections needed to harmonize the 153 volumes as predicted by ComBat. To ensure the regressor learns to predict the corrections needed to 154 harmonize accurately in the presence of AD pathology, we used synthetic minority oversampling 155 technique (SMOTE) for data augmentation<sup>32</sup> before training the random forest regressor. This ensured that IQM values with and without neurodegeneration were equally distributed by removing data 156 157 imbalance between CI and CU individuals. The use of dichotomized cognitive status instead of clinical diagnosis ensured that in the test phase, a full clinical diagnosis is not required as an input to predict 158 the harmonized volumes. The hyperparameters for the random forest regressor were chosen to be 159 the same as the ones used in the original Neuroharmony paper.<sup>15</sup> 160

#### 161 <u>2.4 Model comparisons</u>

162 The performance of the proposed multi-class extension to Neuroharmony was compared with two 163 other machine-learning based harmonization strategies that are generalizable to external datasets:

164 2.4.1 Normative model: In the training phase, volumetric data from only the CU individuals were
 165 harmonized using ComBat harmonization using the aforementioned strategy, while preserving the
 166 effects of age and sex. Subsequently, a random forest regressor was trained to predict the corrections
 167 needed to harmonize the volumes as predicted by ComBat using MRIQC-derived IQM.

168 2.4.2 *Inclusive model*: The training strategy remained the same as for the normative model, but169 volumetric data of both CU and CI individuals were used for training.

#### 170 <u>2.5 Measures for model evaluations</u>

We use two evaluation metrics to assess the ability of the harmonization strategies to remove scanner-related variations in brain-volumetric data between each pair of scanners (biomarker concordance), while retaining the ability to delineate diagnostic groups (preserving disease-related signal).

Firstly, to assess if the volumetric data are harmonized, we compared the distributions of each volumetric measure for each pair of scanners. This was done independently within each diagnostic group, and after correcting for the confounding effects of age and sex by regressing out their effects estimated in CU individuals. The Kolmogorov-Smirnov (KS) test was used for comparing these distributions with the null hypothesis that the distributions between any two pair of scanners were the same. For statistical validity we excluded scanners with fewer than 10 participants of the same diagnostic group from this evaluation. A measure for evaluating harmonization was defined as the

percentage of such comparisons across brain regions for each scanner pair, where distributions were not statistically different from each other ( $p \ge 0.05$ ) after correcting for multiple testing via false discovery rate (FDR). To provide a reference measure for biomarker concordance, we also computed this measure in the non-harmonized data.

Secondly, to assess if disease-related signal was preserved in the volumetric measures, we used area under the receiver operating characteristic (ROC) curve (AUC) as an auxiliary evaluation measure. The ROC curve for distinguishing CN participants from AD patients was computed independently for each volumetric measure. A reference measure for AUC was also computed for the non-harmonized dataset.

#### 191 <u>2.6 Cross-validation experiments</u>

We performed two experiments in a cross-validation framework. Experiment 1 assessed concordance
of the three harmonization strategies, by performing cross-validation at the scanner-level. Experiment
2 performed cross-validation at the participant level, using the best-performing scanner-level
harmonization models.

196 Experiment 1: To investigate the generalizability of the model to unseen scanners (not included in the 197 training set), we performed 5-fold cross-validation across the 43 available scanners, where in each 198 fold 80% of the scanners were used for training the models, and the remaining 20% of the scanners 199 were used for evaluation. In this experiment, to evaluate the bias introduced by using single-scanner 200 data from the large UKBB cohort, we repeated this experiment for increasing portions of UKBB 201 participants such that when the UKBB data is included in the training data the proportions included 202 were: 10%; 33%; 67%; 100%. However, when UKBB cohort data is used in the test set, we always used 203 100% of the cohort. The non-parametric McNemar Chi-square test was used to compare accuracies 204 across harmonization strategies.

Experiment 2: In this experimental setup, the test set consisted of participants from the scanners which were also present in the training set. We selected the two best performing models from Experiment 1 and performed a stratified 5-fold cross-validation across participants, stratified based on the dichotomized cognitive status. For this, the proportion of the UKBB participants included was also decided based on Experiment 1. To provide a reference measure, we compared the accuracies obtained with the corresponding accuracies obtained in Experiment 1.

#### 211 3 Results

#### 212 <u>3.1 Participants</u>

Table 2 shows descriptive statistics for the combined study sample used in our experiments, which consisted of QC-passed volumetric data from 20,864 participants (53.3% female) from 43 scanners across 11 cohorts. Figure 1 shows age distributions by scanner and cognitive group.

#### 216 <u>3.2 Model evaluation</u>

Figure 2 shows the first result of Experiment 1: biomarker concordance under cross-validation, 217 independently for each diagnostic group and with increasing proportions of the UKBB dataset. 218 219 Reference concordance for non-harmonized dataset are also shown for each diagnostic group for 220 comparison. As expected, concordance for each harmonization strategy were significantly higher than the non-harmonized data for all the diagnostic groups ( $p < 10^{-6}$ ). The use of the inclusive and multi-221 222 class models significantly improved the concordance with respect to the normative model for the diagnostic categories of MCI and AD ( $p < 10^{-6}$ ). For diagnostic groups of CN and SCD, the 223 224 concordance of the multi-class model was significantly higher than the normative model when the proportion of UKBB subjects included was 100% ( $p_{CN} = 0.01, p_{SCD} = 0.02$ ). The inclusive model's 225 concordance for CN and SCD subjects was statistically similar to that of the normative model (p >226 227 0.05).

228 Figure 3 shows the second result of Experiment 1: CN vs AD AUC computed independently for each 229 brain regional volume in the test set. Removing scanner-related differences decreased AUC for all 230 harmonization approaches, potentially due to the imbalance in the number of CN and AD participants 231 in the different scanners. The AUCs of the normative model and multi-class model are slightly lower than non-harmonized volumes ( $\Delta AUC = -0.01$ , paired t-test  $p = 10^{-5}$ ). However, the multi-class 232 model significantly outperformed the inclusive model ( $\Delta AUC = -0.09$ , paired t-test  $p < 10^{-10}$ ), 233 234 indicating relative loss of disease related signal when using the inclusive model harmonization 235 strategy.

#### 236 <u>3.3 Harmonization in seen vs unseen MRI scanners</u>

Figure 4 shows the results of Experiment 2: biomarker concordance as a function of scanners seen vs unseen scanners during model training, for the normative model and the multi-class model. Supplementary Figure 1 shows the same for each brain volume individually. Biomarker concordance of the multi-class model was significantly higher than the normative model for unseen scanners, based on McNemar test for all diagnostic categories ( $p_{CN} = 0.01$ ,  $p_{SCD} = 0.02$ ,  $p_{MCI} < 10^{-6}$ ,  $p_{AD} < 10^{-6}$ ). For seen scanners, the multi-class model harmonization strategy significantly outperformed

- the normative model for the diagnostic groups of CN, MCI, and AD ( $p_{CN} < 10^{-6}$ ,  $p_{MCI} < 10^{-6}$ ,  $p_{AD} < 10^{-6}$
- 244  $10^{-6}$ ), but significantly underperformed for SCD ( $p_{SCD} = 0.02$ ). Harmonization accuracy using the
- 245 multi-class model in a seen scanner (accuracy > 97%) was better for all diagnostic groups than in
- 246 unseen scanners (accuracy < 79%).

#### 247 4 Discussion

We introduced a novel extension to the Neuroharmony harmonization model to train a generalizable 248 249 machine learning model for harmonizing multicentric brain-volumetric data for quantitative neuro-250 radiological assessment of Alzheimer's disease. The data for these evaluation experiments were 251 derived from T1w MRIs acquired with 43 different scanners from 20,864 participants spanning 11 252 cohorts. The newly introduced multi-class model would be helpful in harmonizing volumetric data 253 while using automated methods in clinics and research where there could be data from new scanners 254 not included in training. The trained model has been made openly available at 255 https://www.neugrid2.eu/index.php/edads harmonization/ while the code to train the model has been made available in: <a href="https://github.com/e-dads/Multiclass-Neuroharmony/">https://github.com/e-dads/Multiclass-Neuroharmony/</a>. 256

Our experiments showed that the multi-class model, that accounts for the interaction between disease pathology and image quality metrics to remove scanner-related effects, significantly improved harmonization accuracy for patients in unseen scanners, as compared to normative modelling. For seen scanners, it improved the harmonization accuracy for all diagnostic groups except SCD, potentially due to the low sample size of the SCD group (n=1,376). Additionally, we showed that the multi-class model of Neuroharmony preserves disease-related signature during harmonization.

Harmonization of biomarker data from unseen scanners remains a challenge: biomarker concordance for both normative and multi-class models in unseen scanners was lower than obtained for seen scanners. While this leaves scope for further methodological improvements to harmonization strategies for unseen scanners, it would also be useful to investigate if the achieved harmonization performance is sufficient for the generalizability of machine learning approaches such as classification, subtyping<sup>33</sup>, and brain aging.

The different number of participants used to train the respective models could potentially bias the results against the model which uses a smaller dataset for training (normative model). However, we think this setting is a realistic and fair comparison, because normative modelling always discards data from CI individuals. Through our modifications to the Neuroharmony model, we provided a way to include both CI and CU individuals in the training data, which our experiments show improves harmonization in both seen and unseen scanners while preserving disease-related signature.

The harmonization performance obtained with the normative model in our experiments was lower than reported in the original Neuroharmony paper<sup>15</sup>. We think this is due to removal of sex and age variability in the original Neuroharmony method. We preserved these effects, retaining this biological variability, which we would argue is important for both research studies and future clinical implementation.

280 Some limitations of the original Neuroharmony model<sup>15</sup> also apply to this work as well. The 281 harmonization performance for an individual in the test-set depends on the contrast-to-noise ratio in 282 the T1w MRI and the pipeline cannot guarantee effective harmonization if the ratio is outside the 283 range seen in our training data, and might lead to incorrect harmonization. Secondly, the 284 harmonization performance based on biomarker concordance across scanner-pairs is a surrogate 285 measure to measure consistency in the absence of a ground-truth. To overcome this limitation, it 286 would be useful to measure the harmonization performance for participants scanned with multiple 287 scanners, in the future.

288 An important limitation of this study, as with most research studies in this field, is that the imaging 289 data used predominantly came from the developed Western countries of the EU, US, UK, and 290 Australia. A more generalizable and inclusive machine learning model for harmonization would 291 require data from nations in South-America, Asia, and Africa. This would include low field-strength 292 scanners that are predominantly used in these regions, as well as more diverse biological variation in 293 the training data. Large global consortia such as the UNITED consortium<sup>34</sup> could potentially help in 294 getting access to such diverse neuroimaging data. Further developing Neuroharmony for distributed 295 or federated learning for harmonizing imaging data can also facilitate data inclusion from under-296 represented countries.

297 Challenges in the clinical implementation of the harmonization strategy: while the multi-class model 298 outperformed the normative model in terms of harmonization accuracy, the implementation of the 299 model in memory clinics might require additional work to include cognitive status of a patient during 300 regular radiological workup. Machine learning models could potentially be used to overcome this 301 limitation as it has been shown in recent studies that classifying CI from CN/SCD can be done with high accuracy using MRI<sup>35</sup>. To avoid a circular dependency between the two tasks, we think that developing 302 303 multi-task machine learning models to jointly harmonize and predict cognitive status is an important 304 avenue of future work.

While the current work was focused on the AD spectrum, we expect that our new method will be valuable for impaired cognition in general (e.g.: vascular dementia, frontotemporal dementia, dementia with Lewy bodies). Future work validating harmonization approaches for patients with other types of dementia is crucial for eventual clinical implementation.

In summary, we have generalized the Neuroharmony model to harmonize imaging biomarker data from multisite studies while retaining disease signal that could otherwise be removed by the harmonization procedure. Demonstrating on brain MRI biomarker data from the Alzheimer's disease spectrum, our new method outperforms others on both seen and unseen scanners, making it more

- 313 suitable for clinical applications related to cognitive decline, such as memory clinics and clinical trials
- 314 of new interventions for neurodegenerative diseases.

#### 315 Funding

This study was supported by the Early Detection of Alzheimer's Disease Subtypes (E-DADS) project, an EU Joint Programme — Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). The project is supported under the aegis of JPND through the following funding organizations: United Kingdom, Medical Research Council (MR/T046422/1); Netherlands, ZonMW (733051106); France, Agence Nationale de la Recherche (ANR-19-JPW2–000); Italy, Italian Ministry of Health (MoH); Australia, National Health & Medical Research Council (1191535); Hungary, National Research, Development and Innovation Office (2019–2.1.7-ERA-NET-2020–00008).

This work used the Dutch national e-infrastructure with the support of the SURF Cooperative using grant no. EINF-5353. F.B. is supported by the NIHR Biomedical Research Centre at UCLH. B.W. and Z.V. were supported by Project no. RRF-2.3.1-21-2022-00015, which has been implemented with the support provided by the European Union. B.W. was supported by the Consolidator Researcher program of the Óbuda University.

N.P.O. is supported by a UKRI Future Leaders Fellowship (UK Medical Research Council
 MR/S03546X/1).

# 330 Acknowledgments

The authors would like to thank the developers of the original Neuroharmony algorithm for making the code available, and all the research participants and their families for donating their data for scientific research.

334 Data collection and sharing for ADNI was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense 335 336 award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National 337 Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the 338 following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; 339 BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated 340 company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy 341 342 Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack 343 Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda 344 345 Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is 346 providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by

347 the Foundation for the National Institutes of Health (<u>www.fnih.org</u>). The grantee organization is the 348 Northern California Institute for Research and Education , and the study is coordinated by the 349 Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are 350 disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

351 The AIBL study (https://aibl.org.au) is a consortium between Austin Health, CSIRO, Edith Cowan 352 University, the Florey Institute (The University of Melbourne), and the National Ageing Research 353 Institute. The study has received partial financial support from the Alzheimer's Association (US), the 354 Alzheimer's Drug Discovery Foundation, an Anonymous foundation, the Science and Industry 355 Endowment Fund, the Dementia Collaborative Research Centres, the Victorian Government's Operational Infrastructure Support program, the Australian Alzheimer's Research Foundation, the 356 357 National Health and Medical Research Council (NHMRC), and The Yulgilbar Foundation. Numerous 358 commercial interactions have supported data collection and analyses. In-kind support has also been provided by Sir Charles Gairdner Hospital, Cogstate Ltd, Hollywood Private Hospital, The University of 359 360 Melbourne, and St Vincent's Hospital. The AIBL team wishes to thank all clinicians who referred 361 patients with AD and/or MCI to the study. We also thank all those who took part as subjects in the 362 study for their commitment and dedication to helping advance research into the early detection and causation of AD. We thank all the investigators within the AIBL who contributed to the design and 363 364 implementation of the resource and/or provided data but did not actively participate in the 365 development, analysis, interpretation or writing of this current study.

The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the 366 367 NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), 368 P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 369 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, 370 PhD), P30 AG066444 (PI John Morris, MD), P30 AG066518 (PI Jeffrey Kaye, MD), P30 AG066512 (PI 371 Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), 372 P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI 373 David Bennett, MD), P30 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI 374 375 Eric Reiman, MD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), 376 P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI Stephen 377 378 Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P20 379 380 AG068024 (PI Erik Roberson, MD, PhD), P20 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary

- 381 Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD),
- 382 P30 AG072959 (PI James Leverenz, MD).

### 383 Conflicts of interest

- 384 F.B. is on the steering committee or Data Safety Monitoring Board member for Biogen, Merck,
- 385 ATRI/ACTC and Prothena. F.B. has been a consultant for Roche, Celltrion, Rewind Therapeutics, Merck,
- 386 IXICO, Jansen, Combinostics and has research agreements with Merck, Biogen, GE Healthcare, Roche.
- 387 F.B. and D.C.A. are co-founders and shareholders of Queen Square Analytics Ltd. N.P.O. is a consultant
- 388 for Queen Square Analytics Ltd.

#### 389 Data and code availability

- 390 ADC data can be made available to academic researchers upon reasonable request;
- 391 ADNI and AIBL data are stored at the Laboratory of Neuroimaging at the University of Southern
- 392 California and are available to the general scientific community for download:
- 393 <u>http://adni.loni.usc.edu;</u>
- 394 ArWiBO, EDSD, I-ADNI, OASIS and PharmaCog data are available for all researchers on the NeuGRID2
- 395 platform: <u>https://www.neugrid2.eu/ (https://doi.org/10.17616/R31NJN1E);</u>
- 396 HuBA data can be made available upon reasonable request;
- 397 NACC data is available through the National Alzheimer's Coordinating Center platform:
- 398 <u>https://naccdata.org/;</u>
- 399 UKBB data is available at the UK Biobank platform: <u>https://www.ukbiobank.ac.uk/;</u>
- 400 Docker containers for FreeSurfer and MriQC are available on the E-DADS GitHub:
- 401 <u>https://github.com/E-DADS/freesurfer</u>, <u>https://github.com/E-DADS/mriqc</u>;
- 402 Multi-class Neuroharmony harmonization algorithm is available on GitHub:
- 403 <u>https://github.com/88vikram/Multiclass-Neuroharmony;</u>
- 404 Harmonization model files are available for all researchers on the NeuGRID2 platform:
- 405 <u>https://www.neugrid2.eu/index.php/edads\_harmonization.</u>

medRxiv preprint doi: https://doi.org/10.1101/2024.02.01.24302048; this version posted February 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

# perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

#### 407 References

408 Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring 1. 409 Harb Perspect Med. Apr 2012;2(4):a006213. doi:10.1101/cshperspect.a006213 410 2. Ossenkoppele R, Cohn-Sheehy BI, La Joie R, et al. Atrophy patterns in early clinical stages 411 across distinct phenotypes of Alzheimer's disease. Hum Brain Mapp. Nov 2015;36(11):4421-37. 412 doi:10.1002/hbm.22927 413 Hedderich DM, Dieckmeyer M, Andrisan T, et al. Normative brain volume reports may 3. 414 improve differential diagnosis of dementing neurodegenerative diseases in clinical practice. Eur 415 Radiol. May 2020;30(5):2821-2829. doi:10.1007/s00330-019-06602-0 416 Goodkin O, Pemberton H, Vos SB, et al. The quantitative neuroradiology initiative 4. 417 framework: application to dementia. Br J Radiol. Sep 2019;92(1101):20190365. 418 doi:10.1259/bjr.20190365 419 Wang J, Knol MJ, Tiulpin A, et al. Gray Matter Age Prediction as a Biomarker for Risk of 5. 420 Dementia. Proc Natl Acad Sci U S A. Oct 15 2019;116(42):21213-21218. 421 doi:10.1073/pnas.1902376116 422 Young AL, Marinescu RV, Oxtoby NP, et al. Uncovering the heterogeneity and temporal 6. 423 complexity of neurodegenerative diseases with Subtype and Stage Inference. Nat Commun. Oct 15 424 2018;9(1):4273. doi:10.1038/s41467-018-05892-0 425 Liu S, Hou B, Zhang Y, Lin T, Fan X, You H, Feng F. Inter-scanner reproducibility of brain 7. 426 volumetry: influence of automated brain segmentation software. BMC Neurosci. Sep 4 427 2020;21(1):35. doi:10.1186/s12868-020-00585-1 428 8. Gebre RK, Senjem ML, Raghavan S, et al. Cross-scanner harmonization methods for 429 structural MRI may need further work: A comparison study. Neuroimage. Apr 1 2023;269:119912. 430 doi:10.1016/j.neuroimage.2023.119912 431 9. Dewey BE, Zhao C, Reinhold JC, et al. DeepHarmony: A deep learning approach to contrast 432 harmonization across scanner changes. Magn Reson Imaging. Dec 2019;64:160-170. 433 doi:10.1016/j.mri.2019.05.041 434 Fortin JP, Cullen N, Sheline YI, et al. Harmonization of cortical thickness measurements 10. 435 across scanners and sites. Neuroimage. Feb 15 2018;167:104-120. 436 doi:10.1016/j.neuroimage.2017.11.024 437 11. Pagani E, Storelli L, Pantano P, et al. Multicenter data harmonization for regional brain 438 atrophy and application in multiple sclerosis. J Neurol. Jan 2023;270(1):446-459. 439 doi:10.1007/s00415-022-11387-2 440 Zhou HH, Singh V, Johnson SC, Wahba G, Alzheimer's Disease Neuroimaging I. Statistical 12. 441 tests and identifiability conditions for pooling and analyzing multisite datasets. Proc Natl Acad Sci U S 442 A. Feb 13 2018;115(7):1481-1486. doi:10.1073/pnas.1719747115 443 13. Potvin O, Chouinard I, Dieumegarde L, et al. The Canadian Dementia Imaging Protocol: 444 Harmonization validity for morphometry measurements. Neuroimage Clin. 2019;24:101943. 445 doi:10.1016/j.nicl.2019.101943 446 Kia SM, Huijsdens H, Rutherford S, et al. Closing the life-cycle of normative modeling using 14. 447 federated hierarchical Bayesian regression. PLoS One. 2022;17(12):e0278776. 448 doi:10.1371/journal.pone.0278776 449 15. Garcia-Dias R, Scarpazza C, Baecker L, et al. Neuroharmony: A new tool for harmonizing 450 volumetric MRI data from unseen scanners. Neuroimage. Oct 15 2020;220:117127. 451 doi:10.1016/i.neuroimage.2020.117127 452 van der Flier WM, Pijnenburg YA, Prins N, et al. Optimizing patient care and research: the 16. 453 Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41(1):313-27. doi:10.3233/JAD-132306 454 17. Jack CR, Jr., Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative 455 (ADNI): MRI methods. J Magn Reson Imaging. Apr 2008;27(4):685-91. doi:10.1002/jmri.21049

medRxiv preprint doi: https://doi.org/10.1101/2024.02.01.24302048; this version posted February 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

456 18. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study 457 of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal 458 study of Alzheimer's disease. Int Psychogeriatr. Aug 2009;21(4):672-87. 459 doi:10.1017/S1041610209009405 460 Frisoni GB, Prestia A, Zanetti O, et al. Markers of Alzheimer's disease in a population 19. 461 attending a memory clinic. Alzheimers Dement. Jul 2009;5(4):307-17. 462 doi:10.1016/j.jalz.2009.04.1235 Brueggen K, Grothe MJ, Dyrba M, et al. The European DTI Study on Dementia - A multicenter 463 20. 464 DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. Neuroimage. Jan 2017;144(Pt B):305-308. doi:10.1016/j.neuroimage.2016.03.067 465 466 21. Bankó ÉM, Weiss B, Hevesi I, et al. Study protocol of the Hungarian Longitudinal Study of 467 Healthy Brain Aging (HuBA). medRxiv. 2023:2023.11.09.23298159. 468 doi:10.1101/2023.11.09.23298159 469 Cavedo E, Redolfi A, Angeloni F, et al. The Italian Alzheimer's Disease Neuroimaging Initiative 22. 470 (I-ADNI): validation of structural MR imaging. J Alzheimers Dis. 2014;40(4):941-52. doi:10.3233/JAD-471 132666 472 23. Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) 473 database: the Uniform Data Set. Alzheimer Dis Assoc Disord. Jul-Sep 2007;21(3):249-58. 474 doi:10.1097/WAD.0b013e318142774e 475 Marcus DS, Wang TH, Parker J, Csernansky JG, Morris JC, Buckner RL. Open Access Series of 24. 476 Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and 477 demented older adults. J Cogn Neurosci. Sep 2007;19(9):1498-507. doi:10.1162/jocn.2007.19.9.1498 478 25. Galluzzi S, Marizzoni M, Babiloni C, et al. Clinical and biomarker profiling of prodromal 479 Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 480 'European ADNI study'. J Intern Med. Jun 2016;279(6):576-91. doi:10.1111/joim.12482 481 26. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the 482 causes of a wide range of complex diseases of middle and old age. PLoS Med. Mar 483 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779 484 Gorgolewski KJ, Auer T, Calhoun VD, et al. The brain imaging data structure, a format for 27. 485 organizing and describing outputs of neuroimaging experiments. Sci Data. Jun 21 2016;3:160044. 486 doi:10.1038/sdata.2016.44 487 Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of 28. 488 neuroanatomical structures in the human brain. Neuron. Jan 31 2002;33(3):341-55. 489 doi:10.1016/s0896-6273(02)00569-x 490 29. Esteban O, Birman D, Schaer M, Koyejo OO, Poldrack RA, Gorgolewski KJ. MRIQC: Advancing 491 the automatic prediction of image quality in MRI from unseen sites. *PLoS One*. 2017;12(9):e0184661. 492 doi:10.1371/journal.pone.0184661 493 Monereo-Sanchez J, de Jong JJA, Drenthen GS, et al. Quality control strategies for brain MRI 30. 494 segmentation and parcellation: Practical approaches and recommendations - insights from the 495 Maastricht study. Neuroimage. Aug 15 2021;237:118174. doi:10.1016/j.neuroimage.2021.118174 496 31. Matelsky J, Kiar G, Johnson E, Rivera C, Toma M, Gray-Roncal W. Container-Based Clinical 497 Solutions for Portable and Reproducible Image Analysis. J Digit Imaging. Jun 2018;31(3):315-320. 498 doi:10.1007/s10278-018-0089-4 499 32. Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: Synthetic minority over-sampling 500 technique. J Artif Intell Res. 2002;16:321-357. doi:DOI 10.1613/jair.953 501 33. Chen H, Young A, Oxtoby NP, Barkhof F, Alexander DC, Altmann A, investigators A. 502 Transferability of Alzheimer's disease progression subtypes to an independent population cohort. 503 Neuroimage. May 1 2023;271:120005. doi:10.1016/j.neuroimage.2023.120005 504 34. Adams HHH, Evans TE, Terzikhan N. The Uncovering Neurodegenerative Insights Through 505 Ethnic Diversity consortium. Lancet Neurol. Oct 2019;18(10):915. doi:10.1016/S1474-506 4422(19)30324-2

- 507 35. Bron EE, Klein S, Papma JM, et al. Cross-cohort generalizability of deep and conventional
- 508 machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. *Neuroimage Clin*.
- 509 2021;31:102712. doi:10.1016/j.nicl.2021.102712

# 511 Figures and Tables

Manufacturer	Scanner Model	Scanner Model Magnetic Field (T)		
			(Female %)	
Canon	Titan	3.0	581 (43.4%)	
	Discovery MR750	3.0	662 (43.8%)	
	Discovery MR750w	3.0	24 (33.3%)	
	Genesis Signa	1.5	9 (66.7%)	
	Signa Excite	1.5	378 (47.8%)	
GE	Signa PET/MR	3.0	31 (48.3%)	
	Signa HDx	1.5	29 (34.5%)	
	Signa HDx	3.0	99 (44.4%)	
	Signa HDxt	1.5	486 (46.3%)	
	Signa HDxt	3.0	998 (46.4%)	
	Signa Premier	3.0	14 (42.9%)	
	Achieva	1.5	11 (36.3%)	
	Achieva	3.0	295 (60.6%)	
	Achieva dStream	3.0	23 (56.5%)	
	Eclipse	1.5	41 (68.3%)	
	Gemini	3.0	526 (59.3%)	
	Gyroscan NT	1.0	195 (65.1%)	
Philips	Ingenia	3.0	51 (35.3%)	
	Ingenuity	3.0	637 (46.7%)	
	Intera	1.0	436 (63.1%)	
	Intera	1.5	61 (31.1%)	
	Intera	3.0	54 (50.0%)	
	Intera Achieva	1.5	5 (20.0%)	
	Intera Gyroscan	1.5	27 (40.7%)	
	Allegra	3.0	84 (59.5%)	
Siemens	Avanto	1.5	303 (49.5%)	
	Biograph	3.0	5 (0.0%)	
	Espree	1.5	7 (42.8%)	
	Magnetom Expert	1.0	813 (48.8%)	
	Magnetom Impact	1.0	9 (77.8%)	

Magnetom Vida	3.0	20 (30.0%)
Magnetom Vision	1.5	27 (74.1%)
Prisma	3.0	253 (51.8%)
Prima fit	3.0	216 (56.5%)
RCNS	3.0	116 (58.6%)
Skyra	3.0	11181 (54.9%)
Sonata	1.5	415 (45.5%)
Sonata Vision	1.5	5 (60%)
Symphony	1.5	156 (57.7%)
Trio	3.0	62 (66.2%)
Trio Tim	3.0	837 (54.6%)
Verio	3.0	323 (57.6%)
Vision	1.5	359 (64.9%)

512 
 Table 1: Scanners considered in this study and their characteristics.

	Participants	Age [years] <sup>+</sup>	Sex (F/M) <sup>+</sup>	Diagnosis	Unique
	(processed/			(CN / SCD / MCI / AD) $^{\dagger}$	scanners $^{+}$
	considered				
	after removing				
	outliers)				
ADC	4,086 / 3,722	63.9 ± 9.2	1,717 / 2,005	0 / 1,355 / 805 /1562	12
ADNI	2,044 / 1,830	72.2 ± 7.06	889 / 941	687 / 0 / 851 / 292	27
AIBL	557 / 524	72.7 ± 6.5	299 / 225	388 / 0 / 83 / 53	3
ARWiBo	913 / 831	56.3 ± 16.2	529 / 302	603 / 16 / 116 / 96	7
EDSD	416 / 384	70.4 ± 7.3	197 / 187	143 / 0 / 119 / 122	8
HuBA	121 / 116	62.4 ± 6.9	68 / 48	116/0/0/0	1
I-ADNI	179 / 172	72.2 ± 8.0	106 / 66	2 / 5 / 35 / 130	4
NACC	1,861 / 1,731	71.9 ± 9.8	910 / 821	0 / 0 / 949 / 782	22
OASIS	373 / 359	73.2 ± 10.7	233 / 126	211/0/111/37	1
PharmaCog	141 / 137	69.0 ± 7.3	80 / 57	0/0/137/0	7
UKBB	12,259 /	2,259 /			
	11,058	03.3 ± 7.0	0,003 / 4,975	11,030 / 0 / 0 / 0	
Total	22,950 /	65 3 + 0 /	11,111 /	13,208 / 1,376 / 3,206 /	/2
	20,864	05.5 ± 5.4	9,753	3,074	40

514 **Table 2:** Participant Demographics. <sup>+</sup> Values indicated in the column are calculated after removing the outliers, as

bits described in section 2.2. Abbreviations: CN: cognitively normal; SCD: subjective cognitive decline; MCI: mild cognitive

516 impairment; AD: Alzheimer's Disease.



517

518 Figure 1: Diagnosis-wise distributions of age for each scanner in the training cohort. Abbreviations: CN: cognitively normal;

519 SCD: subjective cognitive decline; MCI: mild cognitive impairment; AD: Alzheimer's Disease.



521

522 **Figure 2:** Experiment 1: Biomarker concordance for brain volumes on unseen scanners using different harmonization

523 strategies. Concordance for non-harmonized data has also been shown here as a reference measure for comparison.

524 Abbreviations: CN: cognitively normal; SCD: subjective cognitive decline; MCI: mild cognitive impairment; AD: Alzheimer's

525 Disease.





527 Figure 3: Experiment 1: Boxplots of AUCs for distinguishing CN participants from AD patients in the test set based on the 86

528 brain ROIs considered before and after harmonization. Abbreviations: CN: cognitively normal; AD: Alzheimer's Disease.



530

531 Figure 4: Experiment 2: Accuracy of harmonization for harmonizing brain volumes on seen versus unseen scanners using

MCI

532 normative model and multi-class model. Abbreviations: CN: cognitively normal; SCD: subjective cognitive decline; MCI: mild

AD

533 cognitive impairment; AD: Alzheimer's Disease.

CN

SCD

0.0